CELLINK has initiated the process of changing name to BICO

Report this content

Today, the plans for the name change from CELLINK to BICO have been announced in conjunction with the publication of the notice to the extraordinary general meeting. The new name reflects the Group's strategic bio convergence agenda and emphasizes that the company now comprises a Group consisting of several subsidiaries divided into three business areas. In addition, the journey begins to, over time, build a world-famous company by unleashing the power and future potential of a new brand. The first step in the process for changing name will be through the resolution at the Extraordinary General Meeting on August 6, 2021, and by amending the Articles of Association and thereafter register with the Swedish Companies Registration Office.

CELLINK has carried out extensive brand work in 2021. The aim has been to create a brand strategy that better reflects the Group's development and to better harness the power, strength, and future potential of a new brand. An important component has been to further strengthen the alignment to the Group's strategic bio convergence agenda. This has resulted in a proposal for a new Group name as well as new visual identity with a new logotype which is reflected in the new name, BIo COnvergence.

“In five years, we have built a world-leading group that offers something truly unique – namely a bio convergence revolution. We believe in this concept so strongly that we decided to name the organization after it. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3d printing with biology, we enable our customers to improve people's health and lives for the better. We have always challenged and developed the industry. We will continue to do this in a new context since the new name releases even better opportunities to communicate our offering, our plans going forward, and how we contribute to create the health of the future”, says Erik Gatenholm, CEO.

The proposal to change the company's name applies only to CELLINK AB (publ). The subsidiaries which are part of the Group will keep their names. No changes as a result of the name change will take place for employees within the Group regarding their employment. In the future, the name CELLINK will continue to be used by the wholly owned subsidiary CELLINK Bioprinting AB which develops and sells bioprinters and consumables under the CELLINK brand.

If the name change is approved at the extraordinary general meeting, it also means that the company changes the ticker from CLNK to BICO. Otherwise, there are no changes to the company's financial instruments.

Preliminary Timetable for the name change

  • July 7, 2021: Notice of Extraordinary General Meeting.
  • August 6, 2021: The Extraordinary General Meeting takes place and the proposal to amend the Articles of Association is vetted.
  • Given that the Extraordinary General Meeting approves of the new Articles of Association:
    • Post August 6, 2021: Registration of the new company name with the Swedish Companies Registration Office.
    • August 18, 2021: The new company name will be launched together with new logotype and visual identity in conjunction with the publication of the interim report January-June 2021.
    • Autumn, 2021: Subsequent communication activities to introduce the new company name and the company's bio convergence agenda.

For more information, please contact:

Erik Gatenholm, CEO    
Phone (Sweden): +46 73 267 00 00
Phone (US): +1 (650) 515 5566

E-mail: eg@cellink.com
Isabelle Ljunggren, Head of Communications   
Phone: +46 708 30 08 90    

E-mail: il@cellink.com

The information was submitted for publication, through the agency of the above contact persons, on July 7, 2021, at 5.40pm (CEST).


Founded in 2016, the world-leading bioconvergent company CELLINK provides technology, products and services to create, understand and master biology. Focusing on the application areas of bioprinting, multiomics, cell line development and diagnostics, the company develops and markets innovative technologies that enable researchers in life sciences to grow cells in 3D environments, conduct high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK's products are used in more than 2,000 laboratories including the world's top 20 leading pharmaceutical companies, in more than 65 countries and have been cited in more than 1,700 publications. CELLINK creates the medicine of the future. CELLINK is listed on Nasdaq Stockholm, CLNK B. www.cellink.com